Last updated on September 2020

The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Lymphocytic Leukemia | Lymphocytic Leukemia | Chronic
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • CLL/small lymphocytic lymphoma (SLL) patients.
  • Patients treated with single-agent Ibrutinib (at least one dose) outside interventional clinical trials before January 31, 2019.
  • Serology positive with previous HBV/OBI (HBsAg negatives, anti-HBc positives with or without anti-HBs) infection.
  • Signed written informed consent, if applicable, indicating study scope and procedure understanding.

Exclusion Criteria:

  • Patients who did not undergo hepatitis B screening before starting the Ibrutinib therapy.
  • Patients affected by CLL treated with Ibrutinib vaccinated against hepatitis B or with serology not compatible with a previous infection.
  • Patients affected by HCV, HIV or with other causes of liver disease.
  • Patients enrolled in clinical trials including Ibrutinib administered in combination with other drugs.
  • Patients positive for active hepatitis B.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.